ArticleJournal of cutaneous medicine and surgery2014
Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort Study.
Article in Journal of cutaneous medicine and surgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Pyoderma gangrenosum caused by the molecular uncoupling of OTULIN catalytic activity and LUBAC binding.Nature immunology · 2026Article
- Pyoderma gangrenosum following joint arthroplasty: a comprehensive review of clinical features, diagnosis, and management.Postepy dermatologii i alergologii · 2026Review
- A Rare Case of Pyoderma Gangrenosum as a Complication of Ulcerative Colitis: A Case Report and Literature Review.Clinical case reports · 2025Article
- Pyoderma gangrenosum, peripheral ulcerative keratitis, and oral ulcers in a patient with inflammatory bowel disease.JAAD case reports · 2025Article
- Unveiling the Uncommon: Pyoderma Gangrenosum as an Extraintestinal Complication of Ulcerative Colitis.ACG case reports journal · 2025Article
- Successful Outcome Treating Pyoderma Gangrenosum and Pouchitis With Upadacitinib.ACG case reports journal · 2024Article
- From guts to skin; unmasking risk factors of pyoderma gangrenosum among Crohn's disease patients.Archives of dermatological research · 2024Article
- What can inherited immunodeficiencies reveal about pyoderma gangrenosum?Experimental dermatology · 2024Review
- Dual Biologic Therapy in an Adolescent With Camurati-Engelmann Disease and Crohn Disease.JPGN reports · 2022Article
- Crohn's Disease Diagnosed in a Man with Sarcoidosis: Coincidence or Correspondence?Case reports in gastrointestinal medicine · 2022Article
- Pyoderma gangrenosum with primary sclerosing cholangitis-associated colitis successfully treated with concomitant granulocyte and monocyte adsorption apheresis with corticosteroids.Clinical journal of gastroenterology · 2021Article
- Treatment of Pyoderma Gangrenosum in Pediatric Inflammatory Bowel Disease.JPGN reports · 2020Review
- Perineal pyoderma gangrenosum in pregnancy: A case report.Case reports in women's health · 2019Article
- Comparison of Clinical Features between Pyoderma Gangrenosum Concomitant by Inflammatory Bowel Disease and Idiopathic Pyoderma Gangrenosum.Chinese medical journal · 2017Article
- Differential diagnosis of suspected deep tissue injury.International wound journal · 2016Article
- Assessing Extraintestinal Manifestations of IBD.Gastroenterology & hepatology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPyoderma gangrenosum (PG) is a severe extraintestinal manifestation of inflammatory bowel disease (IBD).
objectiveTo better characterize PG features and management among an IBD cohort.
methodsSubjects with PG were identified using a large database at a tertiary center. Patient demographics and clinical characteristics were summarized using descriptive statistics.
resultsEighty patients with an episode(s) of PG were identified, yielding an overall prevalence of 1.9%. Overall, 93% of patients with PG had some degree of colonic inflammation. Thirty-one (39%) patients required hospitalization for PG. Underlying bowel disease was active at the time of PG episode(s) in 52 (65%) patients. The PG location was variable, with the lower extremity being the most common. Most patients (71.3%) required multiple therapies to achieve PG healing.
conclusionsWe describe one of the largest case series of PG among patients with IBD. The variety of treatment strategies used highlights the lack of clear guidelines in managing this complex group of patients.
Identifiers
25277124PMC5089702W2123547327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.